Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

[1]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[2]  S. Sleijfer,et al.  Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design , 2012, Molecular oncology.

[3]  R. Plummer,et al.  Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[5]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[6]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[7]  R. Kurzrock,et al.  Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience , 2011, Clinical Cancer Research.

[8]  N. Bachl,et al.  No risk – no fun! , 2010 .

[9]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[11]  A. Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[12]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[13]  F. Dekker,et al.  Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[14]  P. Workman,et al.  Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? , 2010, Drug discovery today.

[15]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[16]  G. Giaccone,et al.  Next generation oncology drug development: opportunities and challenges , 2009, Nature Reviews Clinical Oncology.

[17]  J. Verweij.  'No risk, no fun': challenges for the oncology phase I clinical trial time-performance. , 2008, European journal of cancer.

[18]  Flora T. Musuamba,et al.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction , 2008, European Journal of Clinical Pharmacology.

[19]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[20]  R. Andrade,et al.  Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug‐induced liver injury , 2008, Alimentary pharmacology & therapeutics.

[21]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[22]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[23]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[24]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[25]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[26]  M. Rawlins,et al.  Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. , 2000, Journal of hepatology.

[27]  R. Victorino,et al.  Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.

[28]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.